Goldman Sachs Call 400 VRTX 16.01.../ DE000GG22419 /
15/05/2024 11:19:09 | Chg.-0.17 | Bid18:31:18 | Ask18:31:18 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
9.00EUR | -1.85% | 9.55 Bid Size: 3,000 |
9.75 Ask Size: 3,000 |
Vertex Pharmaceutica... | 400.00 USD | 16/01/2026 | Call |
GlobeNewswire
14:05
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
09/05
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
08/05
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
08/05
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
07/05
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
30/04
American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire
27/04
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire
22/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
22/04
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire
09/04
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...
GlobeNewswire
03/04
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
GlobeNewswire
01/04
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
01/04
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...
GlobeNewswire
15/03
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
13/03
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results